BIO-TECHNE Corp Retained Earnings
BIO-TECHNE Corp (TECH) had Retained Earnings of $1.14 billion as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-24
- 2026-06-30: Retained Earnings (Accumulated Deficit) $1.14B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $1.15B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $1.11B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $1.08B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | $1.14B 10-K · filed 2026-08-24 | |
| 2026-03-31 | $1.15B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.11B 10-Q · filed 2026-02-04 | |
| 2025-09-30 | $1.08B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.07B 10-K · filed 2026-08-24 | |
| 2025-03-31 | $1.20B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.29B 10-Q · filed 2025-02-06 | |
| 2024-09-30 | $1.34B 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $1.33B 10-K · filed 2025-08-22 | |
| 2024-03-31 | $1.30B 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $1.26B 10-Q · filed 2024-02-07 | |
| 2023-09-30 | $1.33B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.31B 10-K · filed 2024-08-22 | |
| 2023-03-31 | $1.25B 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $1.20B 10-Q · filed 2023-02-07 | |
| 2022-09-30 | $1.16B 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $1.12B 10-K · filed 2023-08-23 | $1.12B 10-K · filed 2022-08-24 |
| 2022-03-31 | $1.13B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.15B 10-Q · filed 2022-02-07 | |
| 2021-09-30 | $1.12B 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $1.09B 10-K · filed 2022-08-24 | |
| 2021-03-31 | $1.09B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.10B 10-Q · filed 2021-02-08 | |
| 2020-09-30 | $1.07B 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.06B 10-K · filed 2021-08-25 | |
| 2020-03-31 | $1.01B 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $1.04B 10-Q · filed 2020-02-06 | |
| 2019-09-30 | $931.36M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $931.93M 10-K · filed 2020-08-26 | |
| 2019-03-31 | $927.77M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $895.21M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $905.14M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $876.93M 10-K/A · filed 2019-11-06 | |
| 2018-03-31 | $847.31M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $839.56M 10-Q · filed 2018-02-08 | |
| 2017-09-30 | $802.43M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $799.03M 10-K · filed 2018-08-27 | |
| 2017-03-31 | $778.84M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $769.00M 10-Q · filed 2017-02-09 | |
| 2016-09-30 | $774.73M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $770.55M 10-K · filed 2017-09-07 | |
| 2016-03-31 | $756.93M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $738.54M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $724.59M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $713.85M 10-K · filed 2016-08-29 | |
| 2015-03-31 | $699.47M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $687.06M 10-Q · filed 2015-02-09 | |
| 2014-09-30 | $665.71M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $653.28M 10-K · filed 2015-08-31 | |
| 2014-03-31 | $637.92M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $617.72M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $604.10M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $587.73M 10-K · filed 2014-08-29 | |
| 2013-03-31 | $572.19M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $550.12M 10-Q · filed 2013-02-11 | |
| 2012-09-30 | $535.80M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $520.45M 10-K · filed 2013-08-29 | |
| 2012-03-31 | $505.83M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $487.52M 10-Q · filed 2012-02-07 | |
| 2011-09-30 | $479.55M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $472.73M 10-K · filed 2012-08-29 | |
| 2011-03-31 | $454.43M 10-Q · filed 2011-05-10 | |
| 2010-12-31 | $433.39M 10-Q · filed 2011-02-09 | |
| 2010-09-30 | $416.86M 10-Q · filed 2010-11-09 | |
| 2010-06-30 | $400.12M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |